58819-77-5

Usage

Uses

Used in Chemical Research and Development:
6-BROMO-2-METHOXY-3-NITRO-PYRIDINE is used as a reactant for the synthesis of various chemical compounds, contributing to the advancement of the chemical industry. Its unique structure and functional groups make it a valuable intermediate in the preparation of complex molecules.
Used in Pharmaceutical Research and Development:
6-BROMO-2-METHOXY-3-NITRO-PYRIDINE is used as a reactant in the development of new pharmaceuticals, potentially leading to the discovery of novel drugs. Its reactivity and functional groups allow for the creation of diverse chemical entities with potential therapeutic applications.
Used in Material Safety Data Sheets:
6-BROMO-2-METHOXY-3-NITRO-PYRIDINE is referenced in material safety data sheets provided by chemical suppliers, detailing its physical and chemical properties, as well as safety, handling, and storage recommendations. This information is crucial for understanding potential hazards and ensuring the safe use of the compound in research and development settings.

InChI:InChI=1/C6H5BrN2O3/c1-12-6-5(9(10)11)2-4(7)3-8-6/h2-3H,1H3

Upstream product

• 55304-80-8 2,6-dibromo-3-nitropyridine 
• 124-41-4 sodium methylate 

Downstream Products

• 954368-96-8 6-(2-(benzyl-propyl-amino)-ethoxy)-2-methoxy-pyridin-3-ylamine 
• 954368-92-4 6-(1-benzyl-pyrrolidin-3-yloxy)-2-methoxy-pyridin-3-ylamine 
• 954368-95-7 benzyl-[2-(6-methoxy-5-nitro-pyridin-2-yloxy)-ethyl]-propyl-amine 
• 954368-91-3 6-(1-benzyl-pyrrolidin-3-yloxy)-2-methoxy-3-nitro-pyridine 

Relevant academic research and scientific papers

TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a triazine derivative having EGFR inhibitory activity, a preparation method therefor and use thereof. In particular, disclosed are an EGFR inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, use thereof for preparing the EGFR inhibitor, and use thereof in preparing medicaments for treating and/or preventing cancers, tumors or metastatic diseases at least partially related to insertion, deletion or other mutation of EGFR exon 20, and in particular use thereof in preparing medicaments for treating and/or preventing hyperproliferative diseases and diseases inducing cell death disorders. The definition of each substituent of formula (I) is the same as that in the description.

Epidermal growth factor receptor inhibitor and preparation and application thereof

The invention relates to 2-aminopyrimidine derivatives with a structure of a formula (I), a pharmaceutical composition containing the compounds of the formula (I) and application of the compounds in preparation of drugs for prevention or treatment of epidermal growth factor receptor (EGFR) kinase-related diseases, especially application of the compounds in prevention or treatment of cancers related to epidermal growth factor receptor kinase. Substituents in the formula (I) are the same as defined in the description.

Epidermal growth factor receptor inhibitor and preparation and application thereof

The invention relates to 2-aminopyrimidine derivatives with a structure of a formula (I), a pharmaceutical composition containing the compounds of the formula (I) and application of the compounds in preparation of drugs for prevention or treatment of epidermal growth factor receptor (EGFR) kinase-related diseases, especially application of the compounds in prevention or treatment of cancers related to epidermal growth factor receptor kinase. Substituents in the formula (I) are the same as defined in the description.